CHANGES IN THE LEVELS OF ST2 AND GALECTIN-3 IN THE BLOOD SERUM OF PATIENTS WITH ARTERIAL HYPERTENSION
Open Access
- 20 June 2025
- journal article
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 77 (1)
Abstract
Introduction. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 are considered markers of myocardial hypertrophy and fibrosis. Changes in their concentrations are observed in cardiovascular diseases, including arterial hypertension. The aim. To determine threshold values of hypertrophy and fibrosis biomarkers, namely sST2 and galectin-3, in patients with arterial hypertension. Materials and methods. A prospective study was conducted on 82 patients with arterial hypertension (AH). Patients were stratified into two groups based on left ventricular mass index (LVMI) values: Group 1 with left ventricular hypertrophy (LVMI > 115 g/m² for men and 90 g/m² for women, n=33) and Group 2 with normal LVMI values (n=27). Results. Patients with left ventricular hypertrophy exhibited significantly elevated sST2 and galectin-3 levels. Direct correlations were observed between LVMI and sST2 values (r=0.6397; p=0.000) and galectin-3 (r=0.5113; p=0.001). Both biomarkers correlated with various cardiac parameters, including interventricular septal thickness at end-diastole, left atrial diameter, left ventricular end-diastolic diameter, and posterior wall thickness at end-diastole (specifically with sST2). With a selected sST2 value of 17.0 ng/ml, the diagnostic method demonstrated 88.33% accuracy, 92.59% specificity, 93.3% positive predictive value, and 83.33% negative predictive value for hypertrophy. At the chosen galectin-3 level of 29.0 ng/ml, the proposed method achieved 72.22% accuracy, 73.68% sensitivity, 70.59% specificity, 73.68% positive predictive value, and 70.59% negative predictive value. In conclusion, measuring sST2 and galectin-3 biomarkers facilitates the evaluation of left ventricular hypertrophy, serving as an additional tool in assessing cardiac dysfunction and indicating diverse developmental pathways.Keywords
This publication has 21 references indexed in Scilit:
- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of HypertensionJournal Of Hypertension, 2023
- Inhibition of galectin-3 post-infarction impedes progressive fibrosis by regulating inflammatory profibrotic cascadesCardiovascular Research, 2023
- Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- Biomarkers for the diagnosis and management of heart failureHeart Failure Reviews, 2021
- The Diagnostic and Prognostic Value of Galectin-3 in Patients at Risk for Heart Failure with Preserved Ejection Fraction: Results from the DIAST-CHF StudyESC Heart Failure, 2021
- Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing worldCardiovascular Diagnosis and Therapy, 2020
- sST2 for Outcome Prediction in Acute Heart FailureJACC, 2019
- ST2: Current statusIndian Heart Journal, 2018
- Myocardial Interstitial Fibrosis in Heart FailureJACC, 2018
- Relationship Between Left Ventricular Geometry and Soluble ST2 in a Cohort of Hypertensive PatientsThe Journal of Clinical Hypertension, 2013